ArticleDepression and anxiety2018
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
Article in Depression and anxiety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis.Translational psychiatry · 2025Pooled it
- Training emotion recognition in depression-An experimental study.The British journal of clinical psychology · 2025Trial
- Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.Translational psychiatry · 2025Trial
- Gender Differences in Psychological Outcomes Following Surf versus Hike Therapy among U.S. Service Members.International journal of environmental research and public health · 2024Trial
- Modifiable predictors of nonresponse to psychotherapies for late-life depression with executive dysfunction: a machine learning approach.Molecular psychiatry · 2021Trial
- Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry.Biological psychiatry · 2026Review
- From uniform pharmacotherapy to precision psychiatry: reinforcement sensitivity associations with SSRI outcomes.Psychopharmacology · 2026Article
- Association of psychosocial factors and biological pathways identified from rare-variant analysis with longitudinal trajectories of treatment response in major depressive disorder.BMC psychiatry · 2025Article
- Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.Translational psychiatry · 2024Article
- Trajectories of improvement with repetitive transcranial magnetic stimulation for treatment-resistant major depression in the BRIGhTMIND trial.Npj mental health research · 2024Article
- The neural signature of psychomotor disturbance in depression.Molecular psychiatry · 2024Article
- Temporal multi-step predictive modeling of remission in major depressive disorder using early stage treatment data; STAR*D based machine learning approach.Journal of affective disorders · 2023Article
- Predicting treatment outcome in depression: an introduction into current concepts and challenges.European archives of psychiatry and clinical neuroscience · 2023Review
- Typical disease courses of patients with unipolar depressive disorder after in-patient treatments-results of a cluster analysis of the INDDEP project.Frontiers in psychiatry · 2023Article
- A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.Molecular psychiatry · 2022Review
- Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response.BMC psychiatry · 2020Article
- Optimising treatment decision rules through generated effect modifiers: a precision medicine tutorial.BJPsych open · 2019Article
- Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models.Translational psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDefinition of response is critical when seeking to establish valid predictors of treatment success. However, response at the end of study or endpoint only provides one view of the overall clinical picture that is relevant in testing for predictors. The current study employed a classification technique designed to group subjects based on their rate of change over time, while simultaneously addressing the issue of controlling for baseline severity.
methodsA set of latent class trajectory analyses, incorporating baseline level of symptoms, were performed on a sample of 344 depressed patients from a clinical trial evaluating the efficacy of cognitive behavior therapy and two antidepressant medications (escitalopram and duloxetine) in patients with major depressive disorder.
resultsAlthough very few demographic and illness-related features were associated with response rate profiles, the aggregated effect of candidate genetic variants previously identified in large pharmacogenetic studies and meta-analyses showed a significant association with early remission as well as nonresponse. These same genetic scores showed a less compelling relationship with endpoint response categories. In addition, consistent nonresponse throughout the study treatment period was shown to occur in different subjects than endpoint nonresponse, which was verified by follow-up augmentation treatment outcomes.
conclusionsWhen defining groups based on the rate of change, controlling for baseline depression severity may help to identify the clinically relevant distinctions of early response on one end and consistent nonresponse on the other.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.